Clinical relevance of the 21-gene Recurrence Score® assay in treatment decisions for patients with node-positive breast cancer in the genomic era

NPJ Breast Cancer
Eleftherios P MamounasKathy S Albain

Abstract

In contemporary management of early-stage breast cancer, clinical decisions regarding adjuvant systemic therapy are increasingly made after considering both genomic assay results and clinico-pathologic features. Genomic information augments the prognostic information gleaned from clinico-pathologic features by providing risk estimates for distant recurrence and/or breast cancer-specific survival based on individual tumor biology. The 21-gene Oncotype DX Breast Recurrence Score® (RS) assay is validated to be prognostic and predictive of chemotherapy benefit in patients with hormone receptor-positive (HR+), HER2-negative early-stage breast cancer, regardless of nodal status. Because patients frequently are recommended to receive adjuvant chemotherapy based on the perceived poor prognosis related to a positive nodal status, inconsistent use of any prognostic genomic assay in the node-positive (N+) setting likely results in overtreatment of some patients, particularly those with a low genomic risk as defined by the RS test. This comprehensive review of the evidence for the RS assay in patients with N+, HR+, HER2-negative early-stage breast cancer focuses on outcomes of patients with low RS results treated with hormonal therapy alon...Continue Reading

References

Jan 1, 1997·CA: a Cancer Journal for Clinicians·W L Donegan
May 16, 2002·Journal of Mammary Gland Biology and Neoplasia·D F HayesV Stearns
Dec 14, 2004·The New England Journal of Medicine·Soonmyung PaikNorman Wolmark
May 25, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Soonmyung PaikNorman Wolmark
Oct 10, 2009·Journal of the National Cancer Institute·Richard M SimonDaniel F Hayes
Dec 2, 2014·Breast Cancer Research : BCR·Hatem A Azim, Ann H Partridge
Sep 1, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E SenkusUNKNOWN ESMO Guidelines Committee
Sep 24, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Karla V Ballman
Sep 29, 2015·The New England Journal of Medicine·Joseph A SparanoGeorge W Sledge
Feb 10, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lyndsay N HarrisUNKNOWN American Society of Clinical Oncology
Apr 21, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G Curigliano, A Goldhirsch
Jun 5, 2018·The New England Journal of Medicine·Joseph A SparanoGeorge W Sledge

❮ Previous
Next ❯

Citations

Sep 25, 2019·Cancer Medicine·Irene Zarcos-PedrinaciUNKNOWN REDISSEC-CaMISS Group
Sep 26, 2019·Radiology and Oncology·Tanja OvcaricekErika Matos
May 28, 2020·The Breast Journal·Gulisa Turashvili, Hannah Y Wen
Mar 28, 2020·Current Breast Cancer Reports·Julie K JangNaomi R Schechter
Mar 6, 2021·Frontiers in Oncology·Maroun Bou ZerdanHazem I Assi
Mar 7, 2021·International Journal of Molecular Sciences·Jinsha LiuSepideh Afshar
Feb 19, 2021·The Breast : Official Journal of the European Society of Mastology·Serafin Morales MurilloAntonieta Salud Salvia
Nov 12, 2021·International Journal of Radiation Oncology, Biology, Physics·Daegan SitAlan Nichol

❮ Previous
Next ❯

Software Mentioned

Clalit
TAILORx
RxPONDER

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.